期刊文献+

胃肠激素与多囊卵巢综合征的研究探索 被引量:3

Research advances of gastrointestinal hormones and polycystic ovary syndrome
下载PDF
导出
摘要 多囊卵巢综合征(PCOS)是青春期及育龄期女性常见的一种临床综合征,主要表现为月经稀发/无排卵、卵巢多囊样表现和高雄激素血症,常伴有血脂异常、胰岛素抵抗、糖耐量受损等代谢异常,最终可导致2型糖尿病、心脑血管疾病和子宫内膜癌,严重威胁女性的健康。PCOS发病机制目前尚不明确,超过60%的PCOS患者为超重或肥胖。食欲及能量摄入的调节在体质量管理中发挥重要的作用。胃肠道是食物消化吸收的主要场所,也是人体较大的内分泌器官之一。胃、近端小肠和远端小肠上存在一类特殊的上皮细胞可以分泌胃饥饿素、胆囊收缩素、胰高血糖素样肽-1和酪酪肽等激素,这些胃肠激素参与了食欲调节的过程,故又称为"食欲调节激素"。该文着重阐述了PCOS患者胃肠激素分泌的改变及与胃肠激素相关的减重治疗。 Polycystic ovary syndrome (PCOS) is a common syndrome in adolescent women and women of reproductive age. Main manifestations are oligomenorrhea, anovulation, polycystic ovarian, and hyperandrogenism with metabolic abnormalities such as dyslipidemia, insulin resistance, and glucose intolerance. PCOS can lead to type 2 diabetes mellitus, cardiovascular diseases, and endometrial cancer, which seriously threat the health of women. The pathogenesis of PCOS is not clear. Over 60% of women with PCOS are obese or overweight. Appetite and energy intake regulation plays an important role in body weight management. Nutrients are mainly digested and absorbed in gastrointestinal track, which is also one of the largest endocrine organs in human body. Special endocrine epithelial cells in stomach, proximal small intestine, and distal small intestine can secrete ghrelin, CCK, GLP-1, and PYY, which involve in the regulation of appetite and are also known as appetite regulating hormones. This review focuses on changes in the secretion of gastrointestinal hormones and related weight loss treatment in patients with PCOS.
作者 钱程 杨蔚 麻静 QIAN Cheng YANG Wei MA Jing(Department of Endocrinology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai200127, China)
出处 《上海交通大学学报(医学版)》 CAS CSCD 北大核心 2017年第3期414-419,共6页 Journal of Shanghai Jiao tong University:Medical Science
基金 上海市科学技术委员会课题(14441903502) 上海市卫生局科研课题(20124273) 上海交通大学医学院附属仁济医院临床科研创新培育基金(PYZY16-020)~~
关键词 胃肠激素 肥胖 多囊卵巢综合征 gastrointestinal hormones obesity polycystic ovary syndrome
  • 相关文献

参考文献1

二级参考文献20

  • 1Han‐xiao Sun,Nan Lu,Xiu Luo,Lin Zhao,Jian‐min Liu.Liraglutide, the glucagon‐like peptide‐1 receptor agonist, has anabolic bone effects in diabetic G oto‐ K akizaki rats 利拉鲁肽,一种胰高血糖素样肽‐1受体激动剂,在糖尿病Goto‐Kakizaki大鼠中具有骨合成代谢作用[J]. Journal of Diabetes . 2015 (4)
  • 2V. A. Gault,R. Lennox,P. R. Flatt.Sitagliptin, a dipeptidyl peptidase‐4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline[J]. Diabetes Obes Metab . 2015 (4)
  • 3J. L. Trevaskis,C. Sun,J. Athanacio,L. D’Souza,M. Samant,K. Tatarkiewicz,P. S. Griffin,C. Wittmer,Y. Wang,C.‐H. Teng,B. Forood,D. G. Parkes,J. D. Roth.Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet‐induced obese and leptin‐deficient rodents[J]. Diabetes Obes Metab . 2015 (1)
  • 4A. Mieczkowska,S. Mansur,B. Bouvard,P. R. Flatt,B. Thorens,N. Irwin,D. Chappard,G. Mabilleau.Double incretin receptor knock-out (DIRKO) mice present with alterations of trabecular and cortical micromorphology and bone strength[J]. Osteoporosis International . 2015 (1)
  • 5Johanna H.M. Driessen,Hein A.W. van Onzenoort,Ronald M.A. Henry,Arief Lalmohamed,Joop P. van den Bergh,Cees Neef,Hubert G.M. Leufkens,Frank de Vries.Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture[J]. Bone . 2014
  • 6Paula L. McClean,Christian H?lscher.Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer’s disease[J]. Neuropharmacology . 2014
  • 7Anne Nissen,Mikkel Christensen,Filip K. Knop,Tina Vilsb?ll,Jens J. Holst,Bolette Hartmann.Glucose-Dependent Insulinotropic Polypeptide Inhibits Bone Resorption in Humans[J]. The Journal of Clinical Endocrinology & Metabolism . 2014 (11)
  • 8Aisling M. Lynch,Nupur Pathak,Yasmin E. Flatt,Victor A. Gault,Finbarr P.M. O’Harte,Nigel Irwin,Peter R. Flatt.Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus[J]. European Journal of Pharmacology . 2014
  • 9Shiying Wu,Ingrid Hopper,Marina Skiba,Henry Krum.Dipeptidyl Peptidase‐4 Inhibitors and Cardiovascular Outcomes: Meta‐Analysis of Randomized Clinical Trials with 55,141 Participants[J]. Cardiovasc Ther . 2014 (4)
  • 10Guillaume Mabilleau,Aleksandra Mieczkowska,Nigel Irwin,Yannick Simon,Maurice Audran,Peter R. Flatt,Daniel Chappard.Beneficial effects of a N-terminally modified GIP agonist on tissue-level bone material properties[J]. Bone . 2014

共引文献3

同被引文献39

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部